Benzimidazoles as potent and orally active mGlu5 receptor antagonists with an improved pk profile

ACS Medicinal Chemistry Letters

Volumn 2, Issue 1, 2011, Pages 58-62

  Carcache, David ^a   Vranesic, Ivo ^a   Blanz, Joachim ^a   Desrayaud, Sandrine ^a   Fendt, Markus ^a   Glatthar, Ralf ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

benzimidazoles; mGlu5; pharmacokinetics

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

RATTUS;

EID: 78651498151     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100215b     Document Type: Article

References (27)

1. Swanson, C. J.; Bures, M.; Johnson, M. P.; Linden, A.-M.; Monn, J. A.; Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat. Rev. Drug Discovery 2005, 4, 131-144
2. Ritzen, A.; Mathiesen, J. M.; Thomsen, C. Molecular Pharmacology and Therapeutic Prospects of Metabotropic Glutamate Receptor Allosteric Modulators Basic Clin. Pharmacol. Toxicol. 2005, 97, 202-2013
3. Knöpfel, T.; Kuhn, R.; Allgeier, H. Metabotropic Glutamate Receptors: Novel Targets for Drug Development J. Med. Chem. 1995, 38, 1417
4. Conn, P. J.; Pin, J. P. Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205
5. Shigemoto, R.; Nomura, S.; Ohishi, H.; Sugihara, H.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of metabotropic glutamate receptor, mGluR5, in the rat brain Neurosci. Lett. 1993, 163, 53
6. Romano, C.; Sesma, M. A.; McDonald, C. T.; O'Malley, K.; Van den Pol, A. N.; Olney, J. W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain J. Comp. Neurol. 1995, 355, 455
7. Rodrigues, S. M.; Bauer, E. P.; Farb, C. R.; Schafe, G. E.; LeDoux, J. E. The Group I Metabotropic Glutamate Receptor mGluR5 Is Required for Fear Memory Formation and Long-Term Potentiation in the Lateral Amygdala J. Neurosci. 2002, 22, 5219
8. Phan, K. L.; Fitzgerald, D. A.; Cortese, B. M.; Seraji-Bozorgzad, N.; Tancer, M. E.; Moore, G. J. Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 T NeuroReport 2005, 16, 183
9. Mathew, S. J.; Price, R. B.; Charney, D. S. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics Am. J. Med. Genet., Part C 2008, 148, 89
10. Zhu, C. Z.; Wilson, S. G.; Mikusa, J. P.; Wismer, C. T.; Gauvin, D. M.; Lynch, J. L., III; Wade, C. L.; Decker, M. W.; Honore, P. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities Eur. J. Pharmacol. 2004, 506, 107
11. Bradbury, M. J.; Campbell, U.; Giracello, D.; Chapman, D.; King, C.; Tehrani, L.; Cosford, N. D. P.; Anderson, J.; Varney, M. A.; Strack, A. M. Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice J. Pharmacol. Exp. Ther. 2005, 313, 395
12. Breysse, N.; Baunez, C.; Spooren, W.; Gasparini, F.; Amalric, M. Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats J. Neurosci. 2002, 22, 5669
13. Chiamulera, C.; Epping-Jordan, M. P.; Zocchi, A.; Marcon, C.; Cottiny, C.; Tacconi, S.; Corsi, M.; Orzi, F.; Conquet, F. Accruing preclinical evidence about metabotropic glutamate 5 receptor antagonists as treatments for drug dependence highlights the irreplaceable contributions of animal studies to the discovery of new medications for human disorders Nat. Neurosci. 2001, 4, 873
14. Keywood, C.; Wakefield, M. ADX10059, a negative allosteric modulator of mGluR5, demonstrates proof of concept for a role in the management of migraine, in a placebo controlled phase 2A study Neuropharmacology 2008, 55, 605
15. Lehmann, A. Novel treatments of GERD: focus on the lower esophageal sphincter Eur. Rev. Med. Pharmacol. Sci. 2008, 12, 103
16. Bear, M. F.; Huber, K. M.; Warren, S. T. The mGluR theory of fragile X mental retardation Trends Neurosci. 2004, 27, 370
17. Spanka, C.; Glatthar, R.; Desrayaud, S.; Fendt, M.; Orain, D.; Troxler, T.; Vranesic, I. Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity Bioorg. Med. Chem. Lett. 2010, 20, 184
18. Knöpfel, T.; Sakaki, J.; Flor, P. J.; Baumann, P.; Sacaan, A. I.; Velicelebi, G.; Kuhn, R.; Allgeier, H. Profiling of trans-azetidine-2,4- dicarboxylic acid at the human metabotropic glutamate receptors mGlu1b, -2, -4a and -5a Eur. J. Pharmacol. 1994, 288, 389
19. Abundances of components are not corrected for different ionization efficiencies in electrospray
20. Compound 6 was prepared by bromination of commercially available 5,6,7,8-tetrahydroimidazo[1,5-a ]pyridine. See Supporting Information for experimental details.
21. Hintermann, S.; Vranesic, I.; Allgeier, H.; Bruelisauer, A.; Hoyer, D.; Lemaire, M.; Moenius, T.; Urwyler, S.; Whitebread, S.; Gasparini, F.; Auberson, Y. P. ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies Bioorg. Med. Chem. 2007, 15, 903
22. Pagano, A.; Rüegg, D.; Litschig, S.; Stoehr, N.; Stierlin, C.; Heinrich, M.; Floersheim, P.; Prezeau, L.; Carroll, F.; Pin, J. P.; Cambria, A.; Vranesic., I.; Flor, P. J.; Gasparini, F.; Kuhn, R. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b] chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors J. Biol. Chem. 2000, 275 (33) 750
23. i: 30 nM) was observed in membranes prepared from cells expressing rat brain tissue (cortex/hippocampus).
24. Selectivity to ionotropic glutamate receptors was assessed with radioligand displacement assays in rat brain membranes at the AMPA (glutamate binding site), kainate (glutamate binding site) and NMDA (glutamate and glycine binding sites) subtypes.
25. Rat plasma protein binding of compounds 15i and 1 were assessed by equilibrium dialysis. 15i showed a free fraction of 1.7% whereas 1 showed a free fraction of 12.7%.
26. Davis, M.; Falls, W. A.; Campeau, S.; Kim, M. Fear-potentiated startle: a neural and pharmacological analysis Behav. Brain Res. 1993, 58, 175
27. Fendt, M.; Fanselow, M. S. The neuroanato-mical and neurochemical basis of conditioned fear Neurosci. Biobehav. Rev. 1999, 23, 743